Changeflow GovPing Pharma & Drug Safety Cancer Treatment Methods Using Tumor Treating F...
Routine Guidance Added Final

Cancer Treatment Methods Using Tumor Treating Fields, Chemotherapy, and Anti-Fibrotic Agents

Email

Summary

The USPTO has published a patent application detailing methods for treating cancer. The application describes compositions and systems involving the concurrent application of tumor treating fields, chemotherapeutic agents, and anti-fibrotic agents to reduce cancer cell viability and tumor growth.

What changed

This document is a published patent application (US20260083726A1) from the USPTO, detailing novel methods for cancer treatment. The core innovation involves the combined application of alternating tumor treating fields with chemotherapeutic and anti-fibrotic agents. The abstract specifies that these methods aim to reduce cancer cell viability, treat cancer, and prevent tumor volume increase.

While this is a patent application and not a regulatory rule, it signifies potential future developments in cancer therapy. Companies involved in pharmaceutical development, medical device manufacturing, and healthcare providers should be aware of this technological advancement. No immediate compliance actions are required, but it may influence future research, development, and treatment protocols in oncology.

Source document (simplified)

← USPTO Patent Applications

COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS, CHEMOTHERAPEUTIC AGENTS, AND ANTI-FIBROTIC AGENTS

Application US20260083726A1 Kind: A1 Mar 26, 2026

Inventors

Gitit LAVY-SHAHAF, Tali Voloshin-Sela, Lilach Avigdor

Abstract

Compositions, systems, and methods for reducing viability of cancer cells and treating cancer, as well as preventing an increase of volume of a tumor present in a body of a living subject, are disclosed. The systems and methods involve application of an alternating field concurrently with administration of at least one chemotherapeutic agent and at least one anti-fibrotic agent.

CPC Classifications

A61K 31/495 A61K 31/337 A61K 31/4178 A61K 31/436 A61K 31/47 A61K 31/496 A61K 31/505 A61K 31/506 A61K 31/5377 A61K 31/704 A61K 31/7048 A61K 33/243 A61P 35/00 A61N 1/36002

Filing Date

2025-09-22

Application No.

19335499

View original document →

Named provisions

Compositions, Systems, and Methods for Treating Cancer Using Tumor Treating Fields, Chemotherapeutic Agents, and Anti-Fibrotic Agents

Classification

Agency
USPTO
Instrument
Guidance
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260083726A1

Who this affects

Applies to
Drug manufacturers Medical device makers Patients Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing 3345 Medical Device Manufacturing 6211 Healthcare Providers
Activity scope
Cancer Treatment Drug Development Medical Device Technology
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Research & Development
Compliance frameworks
FDA 21 CFR Part 11 GxP
Topics
Medical Devices Healthcare

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: Patent Apps - Pharma (A61K) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.